Holding(s) in Company

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Verona Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Vivo Ventures VII, LLC

4. Full name of shareholder(s) (if different from 3.):iv

Vivo Ventures fund VII, LP

Vivo Ventures VII Affiliates Fund, LP

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

April 28, 2017

6. Date on which issuer notified:

April 28, 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

9.84% to 9.14% Change at Combined Interest Level

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary

GB00B06GSH43

5,047,877

5,047,877

5,047,877

5,047,877

4.83%

ADS

US925050106

0

0

4,507,040

4,507,040

4.31%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

9,554,917

9.14%

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

Vivo Ventures VII, LLC is the general partner of both Vivo Ventures Fund VII, LP (VV Fund VII)

and Vivo Ventures VII Affiliates Fund, LP. (Affiliates Fund VII). Accordingly, Vivo Ventures VII,

LLC may be deemed to have indirect beneficial ownership of shares of the Issuer directly owned

by VV Fund VII and Affiliates Fund VII. As of the date of this filing, VV Fund VII and Affiliates

Fund VII beneficially own 9,351,110 and 203,807 shares of Common Stock respectively.

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Vivo Capital, LLC

Attn: Cinthia Sheu

15. Contact telephone number:

+1-650-688-0818